Ablexis and AlivaMab Biologics (AMB) together offer exceptional, integrated capabilities in efficient, successful biologics drug discovery. Our platforms include a suite of transgenic mice, “AlivaMab® Mouse”, coupled with biologics drug discovery and engineering capabilities for:

• Classic antibody structures
• Single domain VH human antibodies
• Common light chain bispecific antibodies
• scFv and Fab formats
• TCR mimic antibodies
• Diverse panels of CD3 and PD-L1 antibodies ready for engineering into multispecifics

Our platforms are well-validated, including:

• Over a dozen biologics entered in clinical trials by our partners; the most advanced now in Phase 2
• Discovery of antibodies for advanced modalities including membrane multi-spanners (GPCRs, 4-spanners, other transporters), TCR mimics, multispecifics, ADC, CARs, immunocytokines, agonists and antagonists
• Superiority (quality, speed) over other transgenic animal and in vitro display discovery platforms
• Fit-for-Purpose discovery platforms including high-throughput “Function-First”, “Diversity-First”, and single B-cell cloning “Sequence-First”.
• CD3 and PD-L1 antibodies with requisite functional and drug-like qualities